Physician-scientist recognized for groundbreaking research on how the microbiome influences cancer treatment response HOUSTON ― Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to the understanding of melanoma treatment response and resistance to cancer therapies, including groundbreaking discoveries that reveal how the gut microbiome influences responses to immunotherapy. Established originally as the Institute of Medicine in 1970 by the National Academy of […]
M.D.
Antiviral T Cells Safe And Effective For Treating Debilitating Complication Common After Stem Cell Transplants
Cell therapy may provide off-the-shelf treatment for cancer patients with BK virus-associated hemorrhagic cystitis A Phase II trial led by researchers at found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology. Infusion of T cells targeting BKV resulted in rapid responses, […]
Combination therapy significantly improves survival outcomes for patients with acute myeloid leukemia
Adding targeted therapy to chemotherapy in Phase III trial is safe, results in 66% complete remission rate A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. The results were presented in the virtual 25th European Hematology Association (EHA) Annual Congress and were published today in the New England Journal of Medicine. The […]
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
MD Anderson-led Phase I trial of Adaptimmune T-cell receptor therapy sees confirmed responses in multiple cancer types HOUSTON ― The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. Among […]
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
Findings suggest AML treatments may be tailored to individual molecular profiles HOUSTON – A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 […]